Prescient Therapeutics (ASX:PTX) unveils new treatment to boost CAR-T performance

• Prescient Therapeutics (PTX) unveils a novel adjuvant for enhancing cellular immunotherapy
• CellPryme-A was designed to be administered to cancer patients as an intravenous infusion in combination with cellular immunotherapy, such as PTX’s CAR-T cell therapy
• Prescient presented data for the CellPryme-A product at the seventh annual CAR-TCR Summit in Boston
• The company says CellPryme-A is now ready for clinical testing and can be incorporated into clinical studies of existing cell therapies
• Prescient Therapeutics is down 1.35 per cent and trading at 18 cents at 1:29 pm AEST

Prescient Therapeutics (PTX) has unveiled a novel adjuvant for enhancing cellular immunotherapy.

The CellPryme-A product was designed to be administered to cancer patients as an intravenous infusion in combination with cellular immunotherapy, such as PTX’s CAR-T cell therapy. This is used to address the hostile tumour microenvironment that cellular immunotherapies face.  

CellPryme-A can be administered either before or alongside cellular immunotherapy.  

Prescient said in animal models, CellPryme-A had been shown to reduce the number of suppressive regulatory T cells surrounding solid tumours that counteracted the effectiveness of CAR-T and other cancer therapies.

While CellPrymeA demonstrated superior tumour killing and host survival in pre-clinical studies, its effects were even greater when used together with Prescient’s CAR-T manufacturing technology, CellPryme-M.

The company presented this new data at the seventh annual CAR-TCR Summit in Boston.

Prescient Managing Director and CEO Steven Yatomi-Clarke said the company was delighted to “finally” unveil CellPryme-A as a distinct but complementary addition to CellPryme-M.

“Together with Prescient’s next-generation CAR platform, OmniCAR, Prescient has placed itself enviably at the forefront of cellular immunotherapy by creating technologies that overcome the challenges facing the field,” Mr Yatomi-Clarke said.

The company said CellPryme-Awas now ready for clinical testing and could be incorporated into clinical studies of existing cell therapies.

Prescient Therapeutics was down 1.35 per cent and trading at 18 cents at 1:29 pm AEST.